IRBs Punked Again: FDA Sends Warning Letter To Essex IRB For Approving Fictitious Trial
This article was originally published in The Pink Sheet Daily
In an operation highly reminiscent of a government sting three and a half years ago, "Dateline NBC" snares a for-profit IRB using a fictitious protocol.
You may also be interested in...
Institutional review boards appear to be facing vigilante regulation as FDA warns that someone is submitting fictitious studies for review.
Quality has moved up in importance as a criterion for selecting an institutional review board following an April 14 FDA warning letter to Coast IRB and the company's agreement to halt enrollment in clinical studies it monitors
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.